We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$2B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
-7.44%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$699M
AUM Growth
-$155M
(-18%)
Cap. Flow
-$60.3M
Cap. Flow
% of AUM
-8.64%
Top 10 Holdings %
Top 10 Hldgs %
51.76%
Holding
52
New
12
Increased
5
Reduced
17
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$27.7M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$20.8M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$17.2M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$15.6M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$14.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$31.7M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$20.7M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
+$17.2M |
| 4 |
VTYX
Ventyx Biosciences
VTYX
|
+$15M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$14.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $52.8M | 7.55% |
800,000
-550,000
| -41% | -$31.7M |
|
2
IDEAYA Biosciences
IDYA
$3.5B
| $49.4M | 7.07% |
3,600,000
-300,000
| -8% | -$5M |
|
3
Cytokinetics
CYTK
$10.9B
| $44M | 6.3% |
1,250,000
-250,000
| -17% | -$10.2M |
|
4
Immunovant
IMVT
$8.27B
| $38.8M | 5.55% |
2,500,000
-650,000
| -21% | -$11.3M |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $37M | 5.29% |
1,520,000
+20,000
| +1% | +$438K |
|
6
Xenon Pharmaceuticals
XENE
$6.35B
| $32.2M | 4.61% |
900,000
| – | – |
|
7
Sarepta Therapeutics
SRPT
$1.7B
| $30.3M | 4.34% |
220,000
| – | – |
|
|
8
Biogen
BIIB
$30.1B
| $27.8M | 3.98% |
+100,000
| New | +$27.7M |
|
9
Immunocore
IMCR
$1.78B
| $24.7M | 3.54% |
500,000
| – | – |
|
|
ALLK
10
DELISTED
Allakos
ALLK
| $24.6M | 3.53% |
5,536,666
+250,000
| +5% | +$1.6M |
|
11
Viridian Therapeutics
VRDN
$2.17B
| $24.2M | 3.46% |
950,000
-50,000
| -5% | -$1.6M |
|
|
12
Neurocrine Biosciences
NBIX
$17.9B
| $20.2M | 2.9% |
+200,000
| New | +$20.8M |
|
13
Dyne Therapeutics
DYN
$4.19B
| $19.6M | 2.8% |
1,700,000
-450,000
| -21% | -$5.84M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $18.2M | 2.6% |
100,000
-50,000
| -33% | -$9.56M |
|
15
Design Therapeutics
DSGN
$748M
| $16.1M | 2.31% |
2,797,501
| – | – |
|
|
16
Ascendis Pharma A/S
ASND
$16.8B
| $16.1M | 2.3% |
+150,000
| New | +$17.2M |
|
|
BCYC
17
Bicycle Therapeutics
BCYC
$275M
| $16M | 2.28% |
750,000
-685,000
| -48% | -$17.2M |
|
18
Rocket Pharmaceuticals
RCKT
$357M
| $15.4M | 2.21% |
900,000
+150,000
| +20% | +$2.94M |
|
|
AKRO
19
DELISTED
Akero Therapeutics
AKRO
| $15.3M | 2.19% |
400,000
| – | – |
|
|
20
BioMarin Pharmaceuticals
BMRN
$11.7B
| $14.6M | 2.09% |
+150,000
| New | +$15.6M |
|
|
ATXS
21
DELISTED
Astria Therapeutics
ATXS
| $13.9M | 1.99% |
1,044,960
+180,000
| +21% | +$2.43M |
|
|
LKFT
22
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.85B
| $13.5M | 1.94% |
+350,000
| New | +$14.4M |
|
23
Olema Pharmaceuticals
OLMA
$1.07B
| $13M | 1.86% |
3,743,875
| – | – |
|
24
Madrigal Pharmaceuticals
MDGL
$12.9B
| $12.1M | 1.73% |
50,000
-10,000
| -17% | -$2.72M |
|
|
DICE
25
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $11.7M | 1.68% |
410,000
-250,000
| -38% | -$7.4M |
|
Similar funds
MYAM
RCM
LBC
C
CAM
BGM
SC
AF
Logos Global Management's Q1 2023 Portfolio in Review
As of Q1 2023, Logos Global Management held 52 positions worth $699M, down 18% from $854M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Logos Global Management withdrew a net $60.3M in Q1 2023, closing 9 positions and reducing 17 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $20.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.
Against the trend, Logos Global Management opened a new position in Biogen worth $27.8M.
- Logos Global Management's largest Q1 2023 buy was Biogen: 100,000 shares worth $27.8M.
- Logos Global Management added most to Rocket Pharmaceuticals in Q1 2023, an estimated $2.94M increase.
- Logos Global Management's biggest Q1 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $31.7M.
- Logos Global Management fully exited Arcutis Biotherapeutics in Q1 2023, selling an estimated $20.7M.
- Logos Global Management's ten largest holdings make up 52% of its $699M portfolio in Q1 2023.
- Logos Global Management opened 12 new positions and closed 9 in Q1 2023.
- Logos Global Management's portfolio value fell 18% quarter-over-quarter to $699M.
Based on Logos Global Management's 13F filing for Q1 2023, filed 15 May 2023.